Trial · NCT05616013
Adverse events5,274
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 5,274
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Placebo | 0 | 55 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | Bimagrumab 10 mg/kg | 0 | 56 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | Bimagrumab 30 mg/kg | 1 | 57 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | Placebo + Semaglutide 1.0 mg | 1 | 55 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | Placebo + Semaglutide 2.4 mg | 1 | 56 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | Bimagrumab 10 mg/kg + Semaglutide 1.0 mg | 1 | 56 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | Bimagrumab 10 mg/kg + Semaglutide 2.4 mg | 0 | 55 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | Bimagrumab 30 mg/kg + Semaglutide 1.0 mg | 2 | 56 | 2 |
| other | Anaemia | Blood and lymphatic system disorders | Bimagrumab 30 mg/kg + Semaglutide 2.4 mg | 1 | 55 | 1 |
| other | Increased tendency to bruise | Blood and lymphatic system disorders | Placebo | 1 | 55 | 1 |
| other | Increased tendency to bruise | Blood and lymphatic system disorders | Bimagrumab 10 mg/kg | 0 | 56 | 0 |
| other | Increased tendency to bruise | Blood and lymphatic system disorders | Bimagrumab 30 mg/kg | 0 | 57 | 0 |
| other | Increased tendency to bruise | Blood and lymphatic system disorders | Placebo + Semaglutide 1.0 mg | 0 | 55 | 0 |
| other | Increased tendency to bruise | Blood and lymphatic system disorders | Placebo + Semaglutide 2.4 mg | 0 | 56 | 0 |
| other | Increased tendency to bruise | Blood and lymphatic system disorders | Bimagrumab 10 mg/kg + Semaglutide 1.0 mg | 0 | 56 | 0 |
| other | Increased tendency to bruise | Blood and lymphatic system disorders | Bimagrumab 10 mg/kg + Semaglutide 2.4 mg | 0 | 55 | 0 |
| other | Increased tendency to bruise | Blood and lymphatic system disorders | Bimagrumab 30 mg/kg + Semaglutide 1.0 mg | 0 | 56 | 0 |
| other | Increased tendency to bruise | Blood and lymphatic system disorders | Bimagrumab 30 mg/kg + Semaglutide 2.4 mg | 0 | 55 | 0 |
| other | Iron deficiency anaemia | Blood and lymphatic system disorders | Placebo | 0 | 55 | 0 |
| other | Iron deficiency anaemia | Blood and lymphatic system disorders | Bimagrumab 10 mg/kg | 0 | 56 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05616013/events